Sirt result, page-23

1. Maybe not...
   I believe life is about having a balance of choices as a sharehold I know I certainly haven't the right to make these choices for the likes of others! maybe we just need to leave it to the experts and patients to decide the right course of treatment is right for their patients and the patients themselves...?
   
   
   Reposting something I seen on other thread that should be helpful to some shareholders here....
   
   
   Tran777
   1 posts.
   Date:
   23/04/17
   Time:
   10:45:36
   Post #:
   24217218
   imback said: ↑
   At randomization, the pts are divided into 2 groups, SIRT vs Sorafenib
   
   ITT--> intention to treat would look at the results at initial randomization.
   Advantages--> reflects real life,, less bias
   Disadvantages--> may underplay benefits, exaggerate side effects ( eg pt A decides not to proceed with treatment after randomization would still be analysed as failure of treatment)
   
   As per protocol--> eventual treatment received; strict adherence to protocol
   Advantages--> cleaner data
   Disdvantages--> bias introduced ( eg unequal numbers due to cross over of patients from one group to another ).
   
   Overall, for a non inferiority study ( as opposed to a superiority study), both analysis are required.
   
   In this case, the standard of care is Sorafenib. It LOOKS like SIRT is non inferior to the standard of care ( ie less side effects, p value is also very low). BUT it remains to be seen if the survival is equivalent ( as the p-value is high , results may be due to chance)
   
   Will oncologists ( my colleagues ) recommend SIRT?--> yes, as it has less side effects ( remember , these patients are in the category of advanced cancer, hence chance of cure is low. Treatment is mainly to control the disease, with the least possible side effects)
   
   Will investors like the results? --> probable not, due to the ambiguity of the results.
   
   I will be keeping my stop loss tight.
   4
   ReportQuick replyReply with quote
   SRX (ASX)
   Price at posting: $17.00
   Sentiment: Hold
   Disclosure: Held